Collaboration to focus on enhancing physician engagement in clinical trials and cancer research.
Massive Bio and ONCOassist have announced in a joint press release that they have entered into a strategic partnership with the aim of optimizing patient-centric care and enhancing physician engagement in clinical trials and cancer research. As a result of the joint venture, the organizations are hoping to reshape the oncology landscape.
"In the rapidly evolving realm of oncology, our partnership with ONCOassist stands as a testament to our dedication to pushing the boundaries and ensuring every cancer patient receives optimal care,” said Arturo Loaiza-Bonilla, MD, co-founder, chief medical officer, Massive Bio, in the aforementioned press release.
Reference: Massive Bio and ONCOassist® Announce Strategic Partnership at ESMO 2023. BusinessWire. October 19, 2023. Accessed October 25, 2023. https://www.businesswire.com/news/home/20231019250308/en/Massive-Bio-and-ONCOassist%C2%AE-Announce-Strategic-Partnership-at-ESMO-2023
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.